MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2020003455

Медицинская библиотека · Blood advances · 2021

A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant.

Dandoy Christopher E, Rotz Seth, Alonso Priscila Badia, Klunk Anna, Desmond Catherine, Huber John, Ingraham Hannah, Higham Christine, Dvorak Christopher C, Duncan Christine, Schoettler Michelle, Lehmann Leslie, Cancio Maria, Killinger James, Davila Blachy, Phelan Rachel, Mahadeo Kris M, Khazal Sajad, Lalefar Nahal, Vissa Madhav, Myers Kasiani, Wallace Greg, Nelson Adam, Khandelwal Pooja, Bhatla Deepika, Gloude Nicholas, Anderson Eric, Huo Jeffrey, Roehrs Philip, Auletta Jeffery J, Chima Ranjit, Lane Adam, Davies Stella M, Jodele Sonata

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe complication of hematopoietic stem cell transplantation (HSCT). A single-center prospective screening study has shown that the incidence of TA-TMA is much higher than prior retrospective studies that did not systematically screen. These data have not been replicated in a multicenter study. Our objective was to determine the incidence and risk factors for TA-TMA and compare outcomes of pediatric HSCT patients with and without TA-TMA. Patients were prospectively screened for TA-TMA at participating centers using a simple to implement and inexpensive strategy from the start of the preparative regimen through day +100. TA-TMA was diagnosed if ≥4 of 7 laboratory/clinical markers diagnostic for TA-TMA were present concurrently or if tissue histology showed TA-TMA. A total of 614 patients (359 males; 58%) received prospective TA-TMA screening at 13 pediatric centers. TA-TMA was diagnosed in 98 patients (16%) at a median of 22 days (interquartile range, 14-44) posttransplant. Patients with TA-TMA had significantly increased bloodstream infections (38% [37/98] vs 21% [107/51], P ≤ .001), mean total hospitalization days (68; 95% confidence interval [CI], 63-74 vs 43; 95% CI, 41-45; P ≤ .001), and number of days spent in the intensive care unit (10.1; 95% CI, 6.4-14; vs 1.6; 95% CI, 1.1-2.2; P ≤ .001) in the first 100 days after HSCT compared with patients without TA-TMA. Overall survival was significantly higher in patients without TA-TMA (93%; 490/516) compared with patients with TA-TMA (78%; 76/98) (P ≤ .001). These data support the need for systematic screening for TA-TMA and demonstrate the feasibility and efficacy of an easy to implement strategy to do so.

Для цитирования: Dandoy Christopher E, Rotz Seth, Alonso Priscila Badia, Klunk Anna, Desmond Catherine, Huber John, Ingraham Hannah, Higham Christine, Dvorak Christopher C, Duncan Christine, Schoettler Michelle, Lehmann Leslie, Cancio Maria, Killinger James, Davila Blachy, Phelan Rachel, Mahadeo Kris M, Khazal Sajad, Lalefar Nahal, Vissa Madhav, Myers Kasiani, Wallace Greg, Nelson Adam, Khandelwal Pooja, Bhatla Deepika, Gloude Nicholas, Anderson Eric, Huo Jeffrey, Roehrs Philip, Auletta Jeffery J, Chima Ranjit, Lane Adam, Davies Stella M, Jodele Sonata. A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant.. Blood advances. 2021. DOI: 10.1182/bloodadvances.2020003455.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.